Nuclear Medicine Diagnostics Market Report 2026

Nuclear Medicine Diagnostics Market Overview

• Nuclear Medicine Diagnostics market size has reached to $7.88 billion in 2025 • Expected to grow to $13.77 billion in 2030 at a compound annual growth rate (CAGR) of 11.7% • Growth Driver: Surge In Cancer Cases Drives Nuclear Medicine Diagnostics Market • Market Trend: Advancements In Nuclear Medicine Diagnostics Define The Future Of Patient-Centric Solutions • North America was the largest region in 2025.

What Is Covered Under Nuclear Medicine Diagnostics Market?

Nuclear medicine uses radioactive substances inside the body to diagnose illnesses or to target and remove diseased or damaged organs and tissue (for treatment). Nuclear medicine includes the use of radioactive drugs for research, therapeutic, and diagnostic purposes. Radioactive tracers are used in diagnostic nuclear medicine to visualize and/or measure the overall or local function of an organ. The main types of nuclear medicine diagnostics are SPECT radiopharmaceuticals and PET radiopharmaceuticals. A single-photon emission computerized tomography (SPECT) Radiopharmaceuticals refer to gamma-ray tomographic imaging methods that are used in nuclear medicine. The various applications involved are cardiology, thyroid, neurology, oncology and others and the end-users include hospitals and diagnostic centers and research institutes.

What Is The Nuclear Medicine Diagnostics Market Growth Forecast?

The nuclear medicine diagnostics market size is expected to see rapid growth in the next few years. It will grow to $13.77 billion in 2030 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to increasing investments in theranostics, rising adoption of precision oncology diagnostics, expansion of PET imaging infrastructure, growing focus on targeted radiopharmaceutical development, increasing regulatory support for nuclear diagnostics. Major trends in the forecast period include increasing adoption of pet-based diagnostic radiopharmaceuticals, rising demand for personalized nuclear diagnostics, growing integration of imaging and therapeutic applications, expansion of oncology-focused nuclear medicine procedures, enhanced focus on short-half-life radiotracers.

Global Nuclear Medicine Diagnostics Market Segmentation

1) By Type: SPECT Radiopharmaceuticals, PET Radiopharmaceuticals 2) By Application: Cardiology, Thyroid, Neurology, Oncology, Other Applications 3) By End-User: Hospitals And Diagnostic Centers, Research Institutes Subsegments: 1) By SPECT Radiopharmaceuticals: Technetium-99m-Based Radiopharmaceuticals, Iodine-123-Based Radiopharmaceuticals, Thallium-201-Based Radiopharmaceuticals, Other SPECT Radiopharmaceuticals 2) By PET Radiopharmaceuticals: Fluorine-18-Based Radiopharmaceuticals, Carbon-11-Based Radiopharmaceuticals, Gallium-68-Based Radiopharmaceuticals, Other PET Radiopharmaceuticals

What Is The Driver Of The Nuclear Medicine Diagnostics Market?

The increasing prevalence of cancer is expected to propel the growth of the nuclear medicine diagnostics market going forward. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body, which can form a mass or lump called a tumor. The rise in prevalence of cancer is due to the aging global population as cancer incidence increases significantly with age and improved healthcare is extending life expectancy. Nuclear medicine diagnostics is used in the detection, staging, and monitoring of various types of cancer, which contain radioactive substances that can be detected by specialized cameras, creating detailed images of the internal structures and functions of organs and tissues. For instance, in May 2025, according to the National Cancer Institute, a US-based intergovernmental organization, in 2022, nearly 20 million people were diagnosed with cancer and 9.7 million died from it, and by 2050 these figures are projected to climb to 33 million new cases and 18.2 million deaths annually. Therefore, the rising cases of cancer are driving the growth of the nuclear medicine diagnostics industry.

Key Players In The Global Nuclear Medicine Diagnostics Market

Major companies operating in the nuclear medicine diagnostics market are Siemens AG, Bayer Aktiengesellschaft, Novartis AG, GE Healthcare Technologies Inc., Perkin Elmer Inc., Mallinckrodt Pharmaceuticals, Bracco Diagnostics Inc., Lantheus Holdings Inc., IBA Radiopharma Solutions, Curium SAS, Eckert & Ziegler Strahlen- und Medizintechnik AG, Advanced Accelerator Applications, Telix Pharmaceuticals Limited, Nordion (Canada) Inc., NorthStar Medical Technologies LLC, SHINE Medical Technologies LLC, Navidea Biopharmaceuticals Inc., Cyclopharm Limited, Isologic Innovative Radiopharmaceuticals, Clarity Pharmaceuticals Limited, Actinium Pharmaceuticals Inc., Jubilant DraxImage Inc., PharmaLogic Holdings Corp, Institute of Isotopes Co Ltd., Theragnostics Ltd., Eczacıbaşı-Monrol Nuclear Products Co.

Global Nuclear Medicine Diagnostics Market Trends and Insights

Major companies operating in the nuclear medicine diagnostics market are focused on introducing advanced solutions, such as advanced medical technologies, to gain a competitive edge in the market. Advanced medical technologies are cutting-edge technologies in the field of medicine to improve patient outcomes, enhance the standard of care, and promote better health. For instance, in August 2023, Gleneagles Hospital, a Malaysia-based company that provides medical and healthcare services, launched the Nuclear Medicine Unit. The nuclear medicine unit is a specialized facility within a hospital or medical center that is equipped with the latest technology and staffed by highly skilled professionals. This facility is designed to provide early detection, diagnosis, and treatment of diseases using nuclear medicine imaging techniques.

What Are Latest Mergers And Acquisitions In The Nuclear Medicine Diagnostics Market?

In March 2025, GE HealthCare Technologies, Inc., a US based medical technology and pharmaceutical company, acquired Nihon Medi Physics Co., Ltd. (NMP), for an undisclosed amount. With this acquisition, GE HealthCare aims to integrate NMP’s deep expertise in radiopharmaceutical development and manufacturing, thereby increasing its capacity to deliver next generation molecular imaging agents in neurology, cardiology, and oncology. Nihon Medi Physics Co., Ltd. is a Japan based radiopharmaceutical company that offers nuclear medicine diagnostics through its development and supply of radioactive pharmaceuticals for diagnostic nuclear medicine procedures.

Regional Outlook

North America was the largest region in the nuclear medicine diagnostics market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Nuclear Medicine Diagnostics Market?

The nuclear medicine diagnostics market consists of sales of renal scan, bone scan, gallium scan, heart scan, brain scan and breast scan diagnostics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.